Us Physical Therapy Inc (USPH) valuation

NYSE · Health Care

$85.83 -0.85% Close Oct 30, 2026 Live

Us Physical Therapy P/E ratio history

Us Physical Therapy has no meaningful price to earnings ratio at the last close, which happens when earnings over the last twelve months are negative or close to zero. At its last 3 fiscal year ends its P/E ranged from 36.0 (year to Dec 2022) to 48.5 (year to Dec 2020), with a median of 48.2.

P/E at fiscal year endForward P/E at fiscal year end
3040
202020222024
At each fiscal year end. Price is our close on that day; EPS is the fiscal year's diluted earnings per share, both in today's shares.
Fiscal year endedPriceEPSP/EForward P/E
Dec 31, 2025$78.09—n/m—
Dec 31, 2024$88.71$1.8448.231.1
Dec 31, 2023$93.14—n/m33.2
Dec 31, 2022$81.03$2.2536.0—
Dec 31, 2021$95.55—n/m28.8
Dec 31, 2020$120.25$2.4848.5—
Dec 31, 2019$114.35—n/m—
Dec 31, 2018$102.35—n/m—
Dec 31, 2017$72.20—n/m—
Dec 31, 2016$70.20—n/m—

n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.

Us Physical Therapy valuation against its peers

At the close on Oct 30, 2026.
CompanyMarket valueP/EForward P/EPrice / sales
Us Physical TherapyUSPH $1.31B —27.61.6
Tandem Diabetes CareTNDM $1.31B ——1.3
ConmedCNMD $1.33B 18.39.41.0
OmerosOMER $1.33B 10.7—34.8
Opko HealthOPK $1.25B ——2.1
Tyra BiosciencesTYRA $1.25B ———
Innovage HoldingINNV $1.25B —20.41.3
Nutex HealthNUTX $1.38B 7.77.31.6
Amphastar PharmaceuticalsAMPH $1.22B 16.49.91.7
Peer median13.59.61.6

Reading these multiples

The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.

See also: USPH financials · USPH returns

No forecast, no recommendation. This page describes Us Physical Therapy Inc from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.